Companies believe AI isn't delivering because technology moves too fast, so they invest in training and agile frameworks. The real, invisible problems are structural: ambiguous decision rights, siloed data ownership, and misaligned employee incentives. Solving for 'speed' when the foundation is broken guarantees failure.

Training that raises employee enthusiasm for AI tools without embedding deep, contextual judgment is counterproductive. It increases AI use in high-stakes workflows faster than the organization's ability to control for errors, creating a risk funded by the training budget itself and leaving the company more exposed than before.

Off-the-shelf AI models can only go so far. The true bottleneck for enterprise adoption is "digitizing judgment"—capturing the unique, context-specific expertise of employees within that company. A document's meaning can change entirely from one company to another, requiring internal labeling.

Research shows cognitive, accuracy-based skills (like judging if an AI-generated draft is defensible) erode far more quickly than procedural skills (like running a workflow). This means teams lose their most critical risk-management capability—the ability to spot a plausible but incorrect AI output—first.

Unlike fields with vast training data like image recognition, effective drug discovery has too few successful examples for AI to learn from alone. To be useful, AI models must be explicitly taught the foundational principles and complex rules of medicinal chemistry that human experts use.

Large biopharma companies have failed when attempting to use generalist large language models (LLMs) for deal scouting. These models lack the specialized focus and curated data required for the industry, leading to inaccurate results, disappointment, and ultimately, abandoned internal AI projects.

Mandating training modules to boost AI competency is ineffective. It encourages passive behavior, similar to HR compliance training. True competency is only built and measured through hands-on experience and applying the tools to solve real business problems, not through completion certificates.

AI skills decay over time, but cognitive, accuracy-dependent skills (like judging a regulator-facing output) erode three times faster than procedural skills (running a workflow). Companies often measure the slower-decaying half, missing the critical loss of judgment capability, which carries the most regulatory consequence.

The primary reason most pharmaceutical AI projects fail to deliver value is not technical limitation but strategic failure. Organizations become obsessed with optimizing algorithms while neglecting the foundational blueprint that connects AI investment to measurable business outcomes and operational readiness.